3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
3
Sarcoma
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Gastrointestinal Neoplasms
2
Colorectal Neoplasms
2
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Head and Neck Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colonic Diseases
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Interventions
Everolimus
7
lutetium Lu 177 dotatate
4
lanreotide
4
Sunitinib
4
Temozolomide
3
Octreotide
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
Fluorodeoxyglucose F18
3
Capecitabine
3
177Lu-octreotide, DOTA(0)-Tyr(3)-
3
copper dotatate CU-64
2
amino-acid, glucose, and electrolyte solution
2
Quality of Life
2
FAPI-46
2
veliparib
1
tivozanib
1
tislelizumab
1
telotristat ethyl
1
surufatinib
1
romidepsin
1
repotrectinib
1
pralsetinib
1
pembrolizumab
1
pasireotide
1
gallium Ga 68 dotatate
1
gadoteridol
1
gadoterate meglumine
1
gadolinium ethoxybenzyl DTPA
1
gadodiamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
alectinib
×
Gastrointestinal
×
Clear all
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts